227 related articles for article (PubMed ID: 31266388)
1. Metabolism of lysergic acid diethylamide (LSD): an update.
Libânio Osório Marta RF
Drug Metab Rev; 2019 Aug; 51(3):378-387. PubMed ID: 31266388
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.
Luethi D; Hoener MC; Krähenbühl S; Liechti ME; Duthaler U
Biochem Pharmacol; 2019 Jun; 164():129-138. PubMed ID: 30981875
[TBL] [Abstract][Full Text] [Related]
3. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.
De Gregorio D; Comai S; Posa L; Gobbi G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886063
[TBL] [Abstract][Full Text] [Related]
4. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
Marek GJ; Aghajanian GK
J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.
Dolder PC; Schmid Y; Haschke M; Rentsch KM; Liechti ME
Int J Neuropsychopharmacol; 2015 Jun; 19(1):. PubMed ID: 26108222
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an ultra-fast and sensitive microflow liquid chromatography-tandem mass spectrometry (MFLC-MS/MS) method for quantification of LSD and its metabolites in plasma and application to a controlled LSD administration study in humans.
Steuer AE; Poetzsch M; Stock L; Eisenbeiss L; Schmid Y; Liechti ME; Kraemer T
Drug Test Anal; 2017 May; 9(5):788-797. PubMed ID: 27422082
[TBL] [Abstract][Full Text] [Related]
7. Metabolism of lysergic acid diethylamide (LSD) to 2-oxo-3-hydroxy LSD (O-H-LSD) in human liver microsomes and cryopreserved human hepatocytes.
Klette KL; Anderson CJ; Poch GK; Nimrod AC; ElSohly MA
J Anal Toxicol; 2000 Oct; 24(7):550-6. PubMed ID: 11043658
[TBL] [Abstract][Full Text] [Related]
8. Advantages of analyzing postmortem brain samples in routine forensic drug screening-Case series of three non-natural deaths tested positive for lysergic acid diethylamide (LSD).
Mardal M; Johansen SS; Thomsen R; Linnet K
Forensic Sci Int; 2017 Sep; 278():e14-e18. PubMed ID: 28803722
[TBL] [Abstract][Full Text] [Related]
9. The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.
Pouyan N; Younesi Sisi F; Kargar A; Scheidegger M; McIntyre RS; Morrow JD
CNS Drugs; 2023 Dec; 37(12):1027-1063. PubMed ID: 37999867
[TBL] [Abstract][Full Text] [Related]
10. 2-oxo-3-hydroxy-LSD: an important LSD metabolite?
Verstraete AG; Van de Velde EJ
Acta Clin Belg; 1999; 53 Suppl 1():94-6. PubMed ID: 10216992
[TBL] [Abstract][Full Text] [Related]
11. Agonist activity of LSD and lisuride at cloned 5HT2A and 5HT2C receptors.
Egan CT; Herrick-Davis K; Miller K; Glennon RA; Teitler M
Psychopharmacology (Berl); 1998 Apr; 136(4):409-14. PubMed ID: 9600588
[TBL] [Abstract][Full Text] [Related]
12. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
Hungen KV; Roberts S; Hill DF
Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
[TBL] [Abstract][Full Text] [Related]
13. Agonist-directed signaling of serotonin 5-HT2C receptors: differences between serotonin and lysergic acid diethylamide (LSD).
Backstrom JR; Chang MS; Chu H; Niswender CM; Sanders-Bush E
Neuropsychopharmacology; 1999 Aug; 21(2 Suppl):77S-81S. PubMed ID: 10432492
[TBL] [Abstract][Full Text] [Related]
14. Role of the 5-HT
Preller KH; Schilbach L; Pokorny T; Flemming J; Seifritz E; Vollenweider FX
J Neurosci; 2018 Apr; 38(14):3603-3611. PubMed ID: 29555857
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.
Dolder PC; Liechti ME; Rentsch KM
J Clin Lab Anal; 2018 Feb; 32(2):. PubMed ID: 28548305
[TBL] [Abstract][Full Text] [Related]
16. Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD).
Nichols DE
ACS Chem Neurosci; 2018 Oct; 9(10):2331-2343. PubMed ID: 29461039
[TBL] [Abstract][Full Text] [Related]
17. Enzymic formation of dehydrogenated and hydroxylated metabolites from lysergic acid diethylamide by rat liver microsomes.
Inoue T; Niwaguchi T; Murata T
Xenobiotica; 1980 May; 10(5):343-8. PubMed ID: 7415216
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in chromatographic and mass spectrometric methods for determination of LSD and its metabolites in physiological specimens.
Reuschel SA; Eades D; Foltz RL
J Chromatogr B Biomed Sci Appl; 1999 Oct; 733(1-2):145-59. PubMed ID: 10572980
[TBL] [Abstract][Full Text] [Related]
19. Detection of metabolites of lysergic acid diethylamide (LSD) in human urine specimens: 2-oxo-3-hydroxy-LSD, a prevalent metabolite of LSD.
Poch GK; Klette KL; Hallare DA; Manglicmot MG; Czarny RJ; McWhorter LK; Anderson CJ
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(1):23-33. PubMed ID: 10202954
[TBL] [Abstract][Full Text] [Related]
20. Chromatographic and mass spectrometric methods for determination of lysergic acid diethylamide (LSD) and metabolites in body fluids.
Nelson CC; Foltz RL
J Chromatogr; 1992 Sep; 580(1-2):97-109. PubMed ID: 1400834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
